EICHOR
● Completed
Safety and Efficacy of HPP737 in Adult Patients With Plaque Psoriasis
Condition: Psoriasis · Sponsor: Newsoara Biopharma Co., Ltd.
About this study
The goal of this clinical trial is to learn if drug HPP737 works to treat moderate-to-severe plaque psoriasis in adults. It will also learn about the safety of drug HPP737. The main questions it aims to answer are: Does drug HPP737 improve psoriasis severity compared to placebo, as measured by the proportion of patients achieving at least a 75% improvement in the Psoriasis Area and Severity Index (PASI 75) at Day 85? What medical problems do participants have when taking drug HPP737? Researchers will compare drug HPP737 to a placebo (a look-alike substance that contains no drug) to see if drug HPP737 works to treat moderate-to-severe plaque psoriasis. Participants will: Take drug HPP737 or a placebo orally every day Visit the clinic regularly for checkups and tests throughout the study Have their psoriasis severity assessed using standardized scoring tools (PASI, Physician's Global Assessment (PGA), and Body Surface Area ( BSA)) This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial. Eligible participants are adults aged 18 to 70 years with chronic plaque psoriasis for at least 6 months and moderate-to-severe disease at screening.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (8)
| Beijing Friendship Hospital, Capital Medical University | Beijing, China | — |
| Beijing Tsinghua Changgung Hospital | Beijing, China | — |
| Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | Hangzhou, China | — |
| Shandong Provincial Hospital for Skin Diseases, Shandong First Medical University | Jinan, China | — |
| The First People's Hospital of Lianyungang | Lianyungang, China | — |
| Hospital of Dermatology, Chinese Academy of Medical Sciences | Nanjing, China | — |
| Hong Kong University Shenzhen Hospital | Shenzhen, China | — |
| Wuxi No.2 People's Hospital | Wuxi, China | — |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07707141